| Title: |
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma |
| Authors: |
Hájek, R; Minařík, J; Straub, J; Pour, L; Jungova, A; Berdeja, JG; Boccadoro, M; Brozova, L; Spencer, A; Rhee, FV; Vela-Ojeda, J; Thompson, MA; Abonour, R; Chari, A; Cook, G; Costello, CL; Davies, FE; Hungria, VTM; Lee, HC; Leleu, X; Puig, N; Rifkin, RM; Terpos, E; Usmani, SZ; Weisel, KC; Zonder, JA; Bařinová, M; Kuhn, M; Šilar, J; Čápková, L; Galvez, K; Lu, J; Elliott, J; Stull, DM; Ren, K; Maisnar, V |
| Publisher Information: |
Future Medicine |
| Publication Year: |
2021 |
| Collection: |
White Rose Research Online (Universities of Leeds, Sheffield & York) |
| Description: |
Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov) |
| Document Type: |
article in journal/newspaper |
| File Description: |
text |
| Language: |
English |
| ISSN: |
1479-6694 |
| Relation: |
https://eprints.whiterose.ac.uk/id/eprint/173693/6/fon-2020-1225.pdf; Hájek, R, Minařík, J, Straub, J et al. (33 more authors) (2021) Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncology. fon-2020-1225. ISSN: 1479-6694 |
| Availability: |
https://eprints.whiterose.ac.uk/id/eprint/173693/ |
| Rights: |
cc_by_nc_nd_4 |
| Accession Number: |
edsbas.C8B17753 |
| Database: |
BASE |